Cassava Sciences (SAVA) Competitors $1.81 +0.06 (+3.43%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. ETON, CMPX, ZYBT, TECX, SLDB, RZLT, HUMA, ARCT, CYRX, and AQSTShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Eton Pharmaceuticals (ETON), Compass Therapeutics (CMPX), Zhengye Biotechnology (ZYBT), Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), Rezolute (RZLT), Humacyte (HUMA), Arcturus Therapeutics (ARCT), CryoPort (CYRX), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Its Competitors Eton Pharmaceuticals Compass Therapeutics Zhengye Biotechnology Tectonic Therapeutic Solid Biosciences Rezolute Humacyte Arcturus Therapeutics CryoPort Aquestive Therapeutics Cassava Sciences (NASDAQ:SAVA) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership. Do analysts recommend SAVA or ETON? Cassava Sciences currently has a consensus target price of $54.50, indicating a potential upside of 2,911.05%. Eton Pharmaceuticals has a consensus target price of $29.67, indicating a potential upside of 108.19%. Given Cassava Sciences' higher possible upside, equities research analysts plainly believe Cassava Sciences is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, SAVA or ETON? Cassava Sciences has a beta of -2, suggesting that its stock price is 300% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Is SAVA or ETON more profitable? Cassava Sciences has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -9.49%. Eton Pharmaceuticals' return on equity of -3.15% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -87.72% -72.05% Eton Pharmaceuticals -9.49%-3.15%-1.08% Does the media prefer SAVA or ETON? In the previous week, Cassava Sciences and Cassava Sciences both had 5 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.82 beat Cassava Sciences' score of 0.78 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, SAVA or ETON? Eton Pharmaceuticals has higher revenue and earnings than Cassava Sciences. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$24.34M-$1.50-1.21Eton Pharmaceuticals$48.33M7.91-$3.82M-$0.18-79.17 Do insiders & institutionals have more ownership in SAVA or ETON? 38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 12.2% of Cassava Sciences shares are held by insiders. Comparatively, 16.0% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryEton Pharmaceuticals beats Cassava Sciences on 10 of the 14 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.54M$2.42B$5.45B$8.90BDividend YieldN/A1.79%5.36%4.13%P/E Ratio-1.219.1526.3919.66Price / SalesN/A645.63406.37110.24Price / CashN/A21.1625.8827.49Price / Book0.604.487.925.42Net Income-$24.34M$31.16M$3.15B$248.34M7 Day Performance-6.70%0.51%0.66%0.82%1 Month Performance-10.84%10.18%4.95%5.01%1 Year Performance-85.09%1.82%32.31%18.10% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences4.2941 of 5 stars$1.81+3.4%$54.50+2,911.0%-85.3%$84.54MN/A-1.2130News CoverageGap UpETONEton Pharmaceuticals2.6351 of 5 stars$13.51-0.4%$29.67+119.6%+333.1%$362.34M$39.01M-75.0620CMPXCompass Therapeutics3.6217 of 5 stars$2.54+5.8%$13.13+416.7%+160.0%$351.23M$850K-6.2020ZYBTZhengye BiotechnologyN/A$7.43-20.1%N/AN/A$350.47MN/A0.00278News CoverageTECXTectonic Therapeutic2.8761 of 5 stars$18.75-5.4%$82.33+339.1%+20.6%$350.06MN/A-2.56120News CoverageSLDBSolid Biosciences3.4342 of 5 stars$4.51-5.8%$14.90+230.4%-14.1%$349.57M$8.09M-1.51100RZLTRezolute3.0995 of 5 stars$4.03-1.9%$11.83+193.6%+3.7%$344.64MN/A-3.5040HUMAHumacyte2.66 of 5 stars$2.21-4.3%$11.71+430.1%-56.5%$342.82M$1.57M-3.20150Analyst UpgradeGap DownARCTArcturus Therapeutics3.5941 of 5 stars$12.51+1.8%$53.50+327.7%-46.6%$339.27M$152.31M-4.94180News CoverageCYRXCryoPort3.1626 of 5 stars$6.56+3.0%$11.00+67.7%+8.0%$328.92M$228.38M-2.801,186AQSTAquestive Therapeutics1.5181 of 5 stars$3.29+1.2%$10.14+208.3%+27.3%$326.80M$57.56M-5.58160 Related Companies and Tools Related Companies Eton Pharmaceuticals Competitors Compass Therapeutics Competitors Zhengye Biotechnology Competitors Tectonic Therapeutic Competitors Solid Biosciences Competitors Rezolute Competitors Humacyte Competitors Arcturus Therapeutics Competitors CryoPort Competitors Aquestive Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredFine. Don’t believe me. They called me an alarmist... When in 2010 I said America’s debt was out of control. When I warned it w...Porter & Company | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredTrump Makes Major Crypto AnnouncementTrumps “Secret Weapon” for Crypto Dominance There's a growing push for America to lead the next wave of dig...Crypto 101 Media | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
